Why FDA's OOS Expectations Exist: The Barr Laboratories Case
Why FDA expects strict OOS handling: the 1993 Barr Laboratories ruling on retesting, averaging and outlier tests, and how it shaped FDA's OOS guidance.
Why FDA expects strict OOS handling: the 1993 Barr Laboratories ruling on retesting, averaging and outlier tests, and how it shaped FDA's OOS guidance.
Phase I laboratory investigation of an out of specification (OOS) result under US FDA guidance: analyst and supervisor duties, checks and documentation.
Phase II of an OOS investigation under US FDA guidance: production review, retesting, resampling, averaging, outlier tests and batch disposition decisions.
HPLC calibration explained: example calibration parameters and frequencies, with pressure test, drift and noise, oven, flow and gradient checks for QC labs.
Out of specification investigation Phase Ia and Phase Ib explained as per MHRA guidance: obvious errors, laboratory checklist, hypothesis testing and when to go to Phase II.
Understand the MHRA Phase II out-of-specification investigation: hypothesis testing, retesting, resampling, averaging rules and outlier tests, explained for QC and QA staff.
What an out-of-trend (OOT) result is, how it differs from OOS, how stability data are trended, and what MHRA's OOS and OOT investigation guidance expects.
Example SOP for managing reference standards and reference solutions in a QC laboratory: receipt, storage, validity, working standard qualification, labelling and disposal.
Example SOP for good chromatography practices in a pharma QC lab: mobile phase, sequence, system suitability, integration, bracketing standards and data review.
What a sterility test is, how membrane filtration and direct inoculation work, media (FTM, SCDM), 14-day incubation and why it cannot prove sterility (USP <71>, Ph. Eur. 2.6.1).